90915-45-0

Basic information

• Product Name: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)
• Synonyms: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI);8-Methoxy-2-Methyl-4(1H)-quinazolinone;8-Methoxy-2-Methyl-3H-quinazolin-4-one
• CAS NO: 90915-45-0
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.2
• Product Categories: Aromatics
• Mol File: 90915-45-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(90915-45-0)
• EPA Substance Registry System: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(90915-45-0)

Safety Data

• Statements: 22
• Safety Statements: 36/37
• Hazardous Substances Data: 90915-45-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of diverse chemical entities, making it a valuable building block in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) is utilized as a starting material for the synthesis of novel drug candidates. Its structural features enable the design of molecules with potential therapeutic properties, such as anticancer, antiviral, and anti-inflammatory agents.
Used in Agrochemical Industry:
4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) also finds application in the agrochemical industry, where it serves as a precursor for the development of new pesticides and herbicides. Its ability to form a variety of chemical entities allows for the creation of compounds with improved efficacy and selectivity against target pests and weeds.

Upstream product

• 93-26-5 2-methoxyacetanilide 
• 51-79-6 urethane 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 75-05-8 acetonitrile 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 106782-78-9 3-methoxy-2-aminobenzamide 
• 74-88-4 methyl iodide 
• 75-36-5 acetyl chloride 
• 172462-98-5 2-N-Acetylamino-3-methoxybenzamide 
• 54905-94-1 8-methoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one 

Downstream Products

• 102660-84-4 2-(3,4-diethoxy-trans-styryl)-8-methoxy-3H-quinazolin-4-one 
• 101444-64-8 8-methoxy-2-trans-quinazolin-4-one 
• 101731-86-6 8-methoxy-2-(4-methoxy-trans-styryl)-3H-quinazolin-4-one 
• 90417-38-2 8-hydroxy-2-methyl-4(3H)-quinazolinone 
• 105459-51-6 8-hydroxy-2-ethyl-quinazolin-4(3H)-one 
• 154288-17-2 4-chloro-8-methoxy-2-methylquinazoline 
• 104296-30-2 2,3-dimethyl-8-methoxyquinazolin-4-one 
• 387346-77-2 4-[3-(8-methoxy-2-methyl-4-oxo-4H-quinazolin-3-yl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 99071-94-0 8-hydroxy-2,3-dimethyl-quinazolin-4(3H)-one 

Relevant articles and documents

Studies towards hypoxia-activated prodrugs of PARP inhibitors

Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radiotherapy, normal cell toxicity has remained an obstacle to their use in this context. Hypoxia-activated prodrugs (HAPs) provide a means to limit exposure of normal cells to active drug, thus adding a layer of tumor selectivity. We have investigated potential HAPs of model PARPi in which we attach a bioreducible “trigger” to the amide nitrogen, thereby blocking key binding interactions. A representative example showed promise in abrogating PARPi enzymatic activity in a biochemical assay, with a ca. 160-fold higher potency of benzyl phthalazinone 4 than the corresponding model HAP 5, but these N-alkylated compounds did not release the PARPi upon one-electron reduction by radiolysis. Therefore, we extended our investigation to include NU1025, a PARPi that contains a phenol distal to the core binding motif. The resulting 2-nitroimidazolyl ether provided modest abrogation of PARPi activity with a ca. seven-fold decrease in potency, but released the PARPi efficiently upon reduction. This investigation of potential prodrug approaches for PARPi has identified a useful prodrug strategy for future exploration.

A copper-catalyzed Ritter-type cascade via iminoketene for the synthesis of quinazolin-4(3H)-ones and diazocines

We have developed a copper-catalyzed Ritter-type reaction/cyclization cascade of anthranilic acids and nitriles, affording the quinazolin-4(3H)-ones. The cascade proceeds through a Ritter-type reaction capturing the iminoketene intermediates by nitriles. Furthermore, we found a novel Ritter-type reaction/condensation/intramolecular anti-Markovnikov hydroamination cascade, providing access to functionalized diazocines in one-pot.

Total synthesis of penipanoid C, 2-(4-hydroxybenzyl)quinazolin-4(3H)-one and NU1025

The first total synthesis of penipanoid C and 2-(4-hydroxybenzyl)quinazolin-4(3H)-one is reported using a greener mild deep eutectic solvent mediated cyclization strategy with good overall yields. NU1025 drug is also synthesized using the similar protocol.

NEUROLOGICALLY-ACTIVE COMPOUNDS

The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

Methods, compounds and compositions for treating gout

This invention relates to methods of preventing, treating or lessening verity of gout by administration of PARP inhibitors.

Quinazolinone compounds

Phosphate derivatives are disclosed of quinazolinone compounds having structural formula (I) or a pharmaceutically acceptable salt thereof, wherein X' represent hydroxyl, alkyl, alkoxy, or O-Z where Z is a phosphate or phosphate derivative; Y' represents

Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)

Clinical studies concerning the role of poly(ADP-ribose) polymerase (PARP) in the repair of drug- and radiation-induced DNA damage have been impeded by the poor solubility, lack of potency, and limited specificity of currently available inhibitors. A seri

Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors

A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride -X-Y- that represents the grouping (a), (b) or (c )wherein R5 is H, alkyl, aryl or aralkyl.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]

BRADYKININ ANTAGONIST QUINOLINES

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin-or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.